Rashtriya Newsflash

DelveInsight’s report “Oncolytic Virus Therapies Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Oncolytic Virus Therapies landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Oncolytic Virus Therapies market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

Get a Free sample for the Oncolytic Virus Therapies Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market

Some of the key facts of the Oncolytic Virus Therapies Market Report:

• The Oncolytic Virus Therapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In November 2025, November has already brought several noteworthy advancements across the oncology landscape. In just the first two weeks, the FDA has granted multiple approvals and regulatory updates for treatments in breast cancer, leukemia, and gynecologic cancers. Moreover, data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting highlighted emerging therapeutic approaches that may offer benefits across a range of clinical settings.

• In October 2025, In October 2025, the U.S. FDA accepted Replimune’s resubmitted Biologics License Application (BLA) for RP1 in combination with nivolumab (Opdivo®) for patients with advanced, PD-1–refractory melanoma, with a final regulatory decision anticipated by April 2026. Oncolytic viral immunotherapies are an emerging category of cancer treatments that work by directly destroying tumor cells while simultaneously activating the immune system. RP1 (vusolimogene oderparepvec), created by Replimune Inc., is a genetically modified herpes simplex virus type 1 (HSV-1) engineered to selectively replicate within tumors, trigger immunogenic cell death, and boost systemic antitumor immune responses.

• In October 2025, Replimune Group reported that the US FDA has accepted its resubmitted biologics license application (BLA) for RP1 (vusolimogene oderparepvec) combined with nivolumab for treating advanced melanoma in patients who have progressed on prior anti–PD-1 therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of April 10, 2026, reflecting a Class II resubmission review schedule.

• In July 2025, Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company’s allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma.

• In June 2025, Oncolytics Biotech presented a poster demonstrating the role of pelareorep in activating anti-tumor immunity in PDAC.

• In May 2025, Candel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead biological immunotherapy candidate, CAN-2409 (aglatimagene besadenovec), for the treatment of patients with newly diagnosed localized prostate cancer at intermediate-to-high risk. The therapy had previously received FDA Fast Track designation for this indication as well.

• In May 2025, Elicera Therapeutics AB announced that it has signed a Material Transfer Agreement (MTA) with University Hospital Tübingen in Germany. As part of this collaboration, the company’s oncolytic virus candidates, ELC-100 and ELC-201, will be evaluated in studies focused on developing a novel companion diagnostic. This diagnostic aims to predict the potential effectiveness of an emerging immuno-virotherapy approach for treating neuroendocrine neoplasms (NEN).

• In April 2025, Hangzhou ConVerd Co., Ltd. announced that the first patient has been successfully dosed in the Phase IIa clinical trial of hV01, its lead oncolytic vaccinia virus therapy, with the patient reported to be in stable condition. The Phase IIa study is evaluating a single-dose regimen per cycle of hV01, a recombinant human IL-21–based oncolytic poxvirus injection, for the treatment of patients with advanced sarcoma and cervical cancer. The trial specifically targets patients with advanced sarcoma and those with recurrent or metastatic cervical cancer who have no remaining standard treatment options or whose disease has progressed despite existing therapies.

• In 2023, the 7MM reported about 6,631,000 new cases across the selected cancer types, and this number is expected to increase at a CAGR of 1.5% between 2020 and 2034.

• Among these regions, the US accounted for the highest incidence, with roughly 2,893,000 new cases in 2023 a figure anticipated to continue growing through 2034.

• Oncolytic virus therapies are primarily focused on treating cancers that are relapsed or refractory, giving them the potential to address close to 20% of all cancer cases and offering a significant pool of treatable patients.

• Although IMLYGIC was the first therapy of its kind, its sales and revenue have been restricted due to its narrow patient eligibility (only about 10% of patients unable to undergo surgery) and its comparatively lower effectiveness versus other melanoma immunotherapies. As a result, it is expected to maintain only a modest market share in the 7MM over the forecast period.

• Key Oncolytic Virus Therapies Companies: CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharmaceutical, Zhejiang Cancer Hospital, and others

• Key Oncolytic Virus Therapies Therapies: Cretostimogene grenadenorepvec, CF33, IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, OH2 injection, H101, Camrelizumab, and others

• The Oncolytic Virus Therapies market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oncolytic Virus Therapies pipeline products will significantly revolutionize the Oncolytic Virus Therapies market dynamics.

Oncolytic Virus Therapies Overview

Oncolytic virus therapies are a type of cancer treatment that use specially engineered or naturally occurring viruses to infect and destroy cancer cells while sparing healthy cells. Once inside the tumor, these viruses replicate, causing cancer cells to burst and die. They also stimulate the body’s immune system to recognize and attack cancer more effectively. This dual action direct tumor destruction and immune activation makes oncolytic viruses a promising and emerging area in oncology.

To Know in detail about the Oncolytic Virus Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Oncolytic Virus Therapies Market Forecast

Oncolytic Virus Therapies Epidemiology

The Oncolytic Virus Therapies epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Oncolytic Virus Therapies Epidemiology Segmentation:

The Oncolytic Virus Therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Selected Cancer Types in the 7MM

• Target Patient Pool of OVTs by Cancer Types in the 7MM

• Treated Cases by Cancer Types in the 7MM

Download the report to understand which factors are driving Oncolytic Virus Therapies epidemiology trends @ Oncolytic Virus Therapies Epidemiology Forecast

Oncolytic Virus Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Oncolytic Virus Therapies market or expected to get launched during the study period. The analysis covers Oncolytic Virus Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Oncolytic Virus Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Oncolytic Virus Therapies Therapies and Key Companies

• Cretostimogene grenadenorepvec: CG Oncology

• CF33: Imugene

• IMLYGIC (T-VEC): Amgen

• DELYTACT (G47Δ): Daiichio Sankyo

• Olvi-Vec: Genelux

• RP1: Replimune

• OH2 injection: Binhui Biopharmaceutical

• H101, Camrelizumab: Zhejiang Cancer Hospital

Discover more about therapies set to grab major Oncolytic Virus Therapies market share @ Oncolytic Virus Therapies Treatment Landscape

Oncolytic Virus Therapies Market Drivers

• Increasing prevalence of cancer worldwide, driving the demand for novel treatment options.

• Advancements in biotechnology and genetic engineering, facilitating the development of more effective oncolytic viruses.

• Growing investment in research and development by pharmaceutical companies and government agencies.

• Potential for combination therapies with other cancer treatments, enhancing efficacy and patient outcomes.

• Rising awareness among healthcare professionals and patients about the benefits of oncolytic virus therapies.

Oncolytic Virus Therapies Market Barriers

• Limited understanding of the mechanisms of action and long-term safety profiles of oncolytic viruses.

• Challenges in manufacturing and scalability of oncolytic virus production.

• High costs associated with research, development, and clinical trials.

• Regulatory hurdles and approval processes for new oncolytic virus therapies.

• Patient selection and stratification challenges, including variability in treatment responses among different cancer types and patients.

Scope of the Oncolytic Virus Therapies Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Oncolytic Virus Therapies Companies: CG Oncology, Imugene, Amgen, Daiichio Sankyo, Genelux, Replimune, Binhui Biopharmaceutical, Zhejiang Cancer Hospital, and others

• Key Oncolytic Virus Therapies Therapies: Cretostimogene grenadenorepvec, CF33, IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, OH2 injection, H101, Camrelizumab, and others

• Oncolytic Virus Therapies Therapeutic Assessment: Oncolytic Virus Therapies current marketed and Oncolytic Virus Therapies emerging therapies

• Oncolytic Virus Therapies Market Dynamics: Oncolytic Virus Therapies market drivers and Oncolytic Virus Therapies market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Oncolytic Virus Therapies Unmet Needs, KOL’s views, Analyst’s views, Oncolytic Virus Therapies Market Access and Reimbursement

To know more about Oncolytic Virus Therapies companies working in the treatment market, visit @ Oncolytic Virus Therapies Clinical Trials and Therapeutic Assessment

Table of Contents

1. Oncolytic Virus Therapies Market Report Introduction

2. Executive Summary for Oncolytic Virus Therapies

3. SWOT analysis of Oncolytic Virus Therapies

4. Oncolytic Virus Therapies Patient Share (%) Overview at a Glance

5. Oncolytic Virus Therapies Market Overview at a Glance

6. Oncolytic Virus Therapies Disease Background and Overview

7. Oncolytic Virus Therapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Oncolytic Virus Therapies

9. Oncolytic Virus Therapies Current Treatment and Medical Practices

10. Oncolytic Virus Therapies Unmet Needs

11. Oncolytic Virus Therapies Emerging Therapies

12. Oncolytic Virus Therapies Market Outlook

13. Country-Wise Oncolytic Virus Therapies Market Analysis (2020–2034)

14. Oncolytic Virus Therapies Market Access and Reimbursement of Therapies

15. Oncolytic Virus Therapies Market Drivers

16. Oncolytic Virus Therapies Market Barriers

17. Oncolytic Virus Therapies Appendix

18. Oncolytic Virus Therapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/